Literature DB >> 15372693

Synthesis and biological evaluation of a lipid A derivative that contains an aminogluconate moiety.

Balaji Santhanam1, Margreet A Wolfert, James N Moore, Geert-Jan Boons.   

Abstract

A highly convergent strategy for the synthesis of several derivatives of the lipid A of Rhizobium sin-1 has been developed. The synthetic derivatives are 2-aminogluconate 3 and 2-aminogluconolactone 4, both of which lack C-3 acylation. These derivatives were obtained by the preparation of disaccharides in which the two amino groups and the C-3' hydroxy group could be modified individually with acyl or beta-hydroxy fatty acyl groups. Detailed NMR spectroscopy and MS analysis of 3 and 4 revealed that, even under neutral conditions, the two compounds equilibrate. The synthetic compounds lack the proinflammatory effects of Escherichia coli lipopolysaccharide (LPS), as indicated by an absence of tumor necrosis factor production. Although 3 and 4 were able to antagonize E. coli LPS, they were significantly less potent than the synthetic compound 2, which is acylated at C-3, and R. sin-1 LPS; these results indicate that the beta-hydroxy fatty acyl group at C-3 contributes to the antagonistic properties of R. sin-1 LPS. Based on a comparison of the biological responses of the synthetic lipid A derivatives with those of the R. sin-1 LPS and lipid A, the 3-deoxy-D-manno-octulosonic moieties appear to be important for the optimal antagonization of enteric LPS-induced cytokine production.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15372693     DOI: 10.1002/chem.200400376

Source DB:  PubMed          Journal:  Chemistry        ISSN: 0947-6539            Impact factor:   5.236


  10 in total

1.  Synthetic tetra-acylated derivatives of lipid A from Porphyromonas gingivalis are antagonists of human TLR4.

Authors:  Yanghui Zhang; Jidnyasa Gaekwad; Margreet A Wolfert; Geert-Jan Boons
Journal:  Org Biomol Chem       Date:  2008-07-25       Impact factor: 3.876

Review 2.  Progress in the synthesis and biological evaluation of lipid A and its derivatives.

Authors:  Jian Gao; Zhongwu Guo
Journal:  Med Res Rev       Date:  2017-06-16       Impact factor: 12.944

3.  Escherichia coli mutants that synthesize dephosphorylated lipid A molecules.

Authors:  Brian O Ingram; Ali Masoudi; Christian R H Raetz
Journal:  Biochemistry       Date:  2010-09-28       Impact factor: 3.162

4.  Synthesis of a monophosphoryl derivative of Escherichia coli lipid A and its efficient coupling to a tumor-associated carbohydrate antigen.

Authors:  Shouchu Tang; Qianli Wang; Zhongwu Guo
Journal:  Chemistry       Date:  2010-01-25       Impact factor: 5.236

5.  Synthesis of isopeptide epoxide peptidomimetics.

Authors:  Debatosh Majumdar; Matthew D Alexander; James K Coward
Journal:  J Org Chem       Date:  2009-01-16       Impact factor: 4.354

6.  Synthesis and evaluation of monophosphoryl lipid A derivatives as fully synthetic self-adjuvanting glycoconjugate cancer vaccine carriers.

Authors:  Zhifang Zhou; Mohabul Mondal; Guochao Liao; Zhongwu Guo
Journal:  Org Biomol Chem       Date:  2014-04-14       Impact factor: 3.876

7.  Innate immune responses of synthetic lipid A derivatives of Neisseria meningitidis.

Authors:  Yanghui Zhang; Jidnyasa Gaekwad; Margreet A Wolfert; Geert-Jan Boons
Journal:  Chemistry       Date:  2008       Impact factor: 5.236

8.  The influence of the long chain fatty acid on the antagonistic activities of Rhizobium sin-1 lipid A.

Authors:  Yanghui Zhang; Margreet A Wolfert; Geert-Jan Boons
Journal:  Bioorg Med Chem       Date:  2007-05-06       Impact factor: 3.641

9.  Agonistic and antagonistic properties of a Rhizobium sin-1 lipid A modified by an ether-linked lipid.

Authors:  Mahalakshmi Vasan; Margreet A Wolfert; Geert-Jan Boons
Journal:  Org Biomol Chem       Date:  2007-05-29       Impact factor: 3.876

Review 10.  Aminosugar-based immunomodulator lipid A: synthetic approaches.

Authors:  Alla Zamyatina
Journal:  Beilstein J Org Chem       Date:  2018-01-04       Impact factor: 2.883

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.